IS5329A - Flutningskerfi fyrir antígen þar sem monoglýseríðeða díglýseríð afleiður eru ónæmisglæðar - Google Patents

Flutningskerfi fyrir antígen þar sem monoglýseríðeða díglýseríð afleiður eru ónæmisglæðar

Info

Publication number
IS5329A
IS5329A IS5329A IS5329A IS5329A IS 5329 A IS5329 A IS 5329A IS 5329 A IS5329 A IS 5329A IS 5329 A IS5329 A IS 5329A IS 5329 A IS5329 A IS 5329A
Authority
IS
Iceland
Prior art keywords
adjuvant
monoglyceride
transport system
antigen
antigen transport
Prior art date
Application number
IS5329A
Other languages
English (en)
Inventor
Gizurarson Sveinbjörn
Guthmundsdottir Vera
Original Assignee
Lyfjathroun Hf.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyfjathroun Hf. filed Critical Lyfjathroun Hf.
Publication of IS5329A publication Critical patent/IS5329A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cultivation Of Plants (AREA)
IS5329A 1997-07-09 1999-12-29 Flutningskerfi fyrir antígen þar sem monoglýseríðeða díglýseríð afleiður eru ónæmisglæðar IS5329A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IS4518A IS4518A (is) 1997-07-09 1997-07-09 Nýtt lyfjaform fyrir bóluefni
PCT/IS1998/000006 WO1999002186A2 (en) 1997-07-09 1998-07-09 Antigen delivery system comprising monoglyceride or diglyceride derivatives as adjuvant

Publications (1)

Publication Number Publication Date
IS5329A true IS5329A (is) 1999-12-29

Family

ID=36699745

Family Applications (2)

Application Number Title Priority Date Filing Date
IS4518A IS4518A (is) 1997-07-09 1997-07-09 Nýtt lyfjaform fyrir bóluefni
IS5329A IS5329A (is) 1997-07-09 1999-12-29 Flutningskerfi fyrir antígen þar sem monoglýseríðeða díglýseríð afleiður eru ónæmisglæðar

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IS4518A IS4518A (is) 1997-07-09 1997-07-09 Nýtt lyfjaform fyrir bóluefni

Country Status (13)

Country Link
US (2) US6514503B1 (is)
EP (1) EP1003551B1 (is)
JP (1) JP2001509491A (is)
KR (1) KR20010021622A (is)
CN (1) CN1202863C (is)
AT (1) ATE329617T1 (is)
AU (1) AU745849B2 (is)
BR (1) BR9810568A (is)
CA (1) CA2295237A1 (is)
DE (1) DE69834921T2 (is)
ES (1) ES2267189T3 (is)
IS (2) IS4518A (is)
WO (1) WO1999002186A2 (is)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
ES2296390T3 (es) * 1998-05-07 2008-04-16 Corixa Corporation Composicion coadyuvante y procedimiento para su uso.
IL146382A0 (en) * 1999-05-13 2002-07-25 American Cyanamid Co Adjuvant combination formulations
ATE378067T1 (de) * 1999-08-18 2007-11-15 Industy Academic Cooperation F Agent zur induktion einer immunologischen toleranz
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
GB0007465D0 (en) * 2000-03-29 2000-05-17 Amersham Pharm Biotech Uk Ltd Substrate for a lipase enzyme assay
WO2001097841A2 (en) * 2000-06-22 2001-12-27 American Cyanamid Company Qs-21 and il-12 as an adjuvant combination
HRP20030355A2 (en) * 2000-11-10 2005-04-30 Wyeth Holdings Corporation Adjuvant combination formulations
DE60234695D1 (de) * 2001-06-07 2010-01-21 Univ Colorado Mutantenformen von cholera holotoxin als adjuvans
BR0210216A (pt) 2001-06-07 2004-06-08 Wyeth Corp Holotoxina do cólera imunogênica, mutante (ct-crm), composição imunogênica, métodos para aumentar a resposta imune de um hospedeiro vertebrado a um antìgeno, e para produzir uma holotoxina do cólera imunogênica, mutante, sequência ou molécula de ácido nucleico isolado e purificado, célula hospedeira, e, uso de uma holotoxina do cólera mutante
US20040241310A1 (en) * 2001-08-16 2004-12-02 Sveibjorn Gizurarson Method of producing antibodies ex-vivo
WO2003047493A2 (en) * 2001-12-03 2003-06-12 Dor Biopharma Inc. Stabilized reverse micelle compositions and uses thereof
US20050163787A1 (en) * 2002-02-25 2005-07-28 Lyfjathroun Hf, Biopharmaceutical Immunological adjuvant
WO2003070280A2 (en) * 2002-02-25 2003-08-28 Lyfjathroun Hf Absorption enhancing agent
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
CN1720437A (zh) * 2002-11-21 2006-01-11 札幌免疫诊断研究所 唾液的采集及回收器具
WO2004056314A2 (en) * 2002-12-17 2004-07-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
US8685718B2 (en) * 2003-05-20 2014-04-01 New York University Mucosal immunization to prevent prion infection
WO2005019412A2 (en) 2003-05-20 2005-03-03 New York University Mucosal immunization to prevent prion infection
US20060264505A1 (en) * 2003-11-07 2006-11-23 Stiefel Laboratories, Inc. Dermatological compositions
US20050100621A1 (en) * 2003-11-07 2005-05-12 Popp Karl F. Dermatological compositions
CA2545325C (en) * 2003-11-10 2015-01-13 Uab Research Foundation Compositions for reducing bacterial carriage and cns invasion and methods of using same
WO2007015441A1 (ja) 2005-08-01 2007-02-08 Hisamitsu Pharmaceutical Co., Inc. 経皮または経粘膜投与のためのアジュバントおよび製剤
CA2661210A1 (en) * 2006-08-17 2008-02-21 The Uab Research Foundation Diagnosing pneumococcal pneumonia
JP5275047B2 (ja) * 2007-01-31 2013-08-28 久光製薬株式会社 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤
BRPI0721702A2 (pt) * 2007-05-23 2013-01-15 Uab Research Foundation neuraminidase pneumocàcica destoxificada ou uma porÇço antigÊnica da mesma, composiÇço, mÉtodos para reduzir ou prevenir a portabilidade nasal pneumocàcica em um indivÍduo, e para reduzir ou prevenir a infecÇço pneumocàcica em um indivÍduo, e, recipiente
EP2344152A4 (en) * 2008-10-08 2013-04-03 Immune Solutions Ltd ORAL VACCINES FOR PRODUCING MUCOSAL IMMUNITY
CN106386848B (zh) * 2009-03-11 2022-01-11 阿克苏诺贝尔化学品国际有限公司 包含草甘膦和烷氧基化甘油酯的除草配制剂
WO2010114169A1 (en) * 2009-03-31 2010-10-07 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
LT2691530T (lt) 2011-06-10 2018-08-10 Oregon Health & Science University Cmv glikoproteinai ir rekombinantiniai vektoriai
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3064218B1 (en) 2013-10-31 2019-06-19 Hisamitsu Pharmaceutical Co., Inc. Adjuvant composition
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CU24534B1 (es) * 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE545978A (is) * 1955-03-11
FR2253499B1 (is) * 1973-12-10 1977-11-04 Fabre Sa Pierre
US4420484A (en) 1979-08-13 1983-12-13 Sterling Drug Inc. Basic amino or ammonium antimicrobial agent-polyethylene glycol ester surfactant-betaine and/or amine oxide surfactant compositions and method of use therof
DE3225706C2 (de) * 1982-07-09 1984-04-26 A. Nattermann & Cie GmbH, 5000 Köln Flüssige Wirkstofformulierungen in Form von Konzentraten für Mikroemulsionen
JPS60149510A (ja) 1984-01-13 1985-08-07 Kao Corp 農薬組成物
US4610868A (en) 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4771571A (en) * 1986-12-31 1988-09-20 Nabisco Brands, Inc. Method for treating pineapple to prevent pineapple fruit diseases
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
EP0324455A3 (en) 1988-01-15 1991-03-27 Hans O. Ribi Novel polymeric immunological adjuvants
US5190748A (en) * 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US5177091A (en) * 1990-12-06 1993-01-05 Ciba-Geigy Corporation Use of carbazones as novel active ingredients in medicaments
DK0575545T3 (da) * 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider
AU668509B2 (en) 1991-04-19 1996-05-09 Affinity Biotech, Inc. Convertible microemulsion formulations
CA2083553A1 (en) 1991-11-25 1993-05-26 Kuniharu Seki Immunogen composition
GB9207799D0 (en) * 1992-04-09 1992-05-27 Procter & Gamble Aqueous compositions
US5314685A (en) * 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
ATE196254T1 (de) * 1992-10-16 2000-09-15 Ibah Inc Konvertierbare mikroemulsionsformulierungen
IT1255895B (it) * 1992-10-20 1995-11-17 Laura Chiodini Composizioni farmaceutiche contenenti una calcitonina
CA2153780C (en) 1993-01-15 2004-04-13 Micro Vesicular Systems, Inc. Method of inhibiting viral reproduction
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
ES2141950T3 (es) * 1994-08-05 2000-04-01 Inpharma Sa Composiciones que contienen troxerutina complejada con fosfatidilcolina para el tratamiento topico de la impotencia erectil.
FR2729307B1 (fr) * 1995-01-18 1997-04-18 Seppic Sa Utilisation d'esters d'acides gras ethoxyles comme composants auto-emulsionnables notamment utiles pour la preparation de produits de traitement phytosanitaires ou de medicaments a usage veterinaire ou humain
US5744137A (en) * 1995-02-06 1998-04-28 The United States Of America As Represented By The Secretary Of The Agriculture Oil emulsion vaccines prepared with animal, vegetable, and synthetic oils using a mixture of nonionic surfactants
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
EP0833621B1 (en) * 1995-06-09 2002-01-30 R.P. Scherer Technologies, Inc. Soft gelatin capsules containing particulate material
DE69636889T2 (de) * 1995-11-30 2007-12-06 Nof Corp. Öladjuvierter Impfstoff und Verfahren zu seiner Herstellung
SE9602280D0 (sv) * 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
ID18079A (id) * 1996-08-26 1998-02-26 Takeda Chemical Industries Ltd Komposisi farmasi yang mengandung bahan pemercepat osteogenesis
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
FR2773489B1 (fr) * 1998-01-15 2001-03-23 Immunotech Sa Nouvelle composition destinee a la voie oromuqueuse notamment pernasale
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
EP1034792A1 (en) * 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US6495596B1 (en) * 2001-03-23 2002-12-17 Biozibe Laboratories, Inc. Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase-2
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent

Also Published As

Publication number Publication date
US20030099659A1 (en) 2003-05-29
KR20010021622A (ko) 2001-03-15
IS4518A (is) 1999-01-10
CA2295237A1 (en) 1999-01-21
AU745849B2 (en) 2002-04-11
CN1262626A (zh) 2000-08-09
DE69834921T2 (de) 2007-01-18
BR9810568A (pt) 2000-09-19
AU8459898A (en) 1999-02-08
WO1999002186A2 (en) 1999-01-21
JP2001509491A (ja) 2001-07-24
CN1202863C (zh) 2005-05-25
ATE329617T1 (de) 2006-07-15
EP1003551B1 (en) 2006-06-14
ES2267189T3 (es) 2007-03-01
WO1999002186A3 (en) 1999-04-01
US6514503B1 (en) 2003-02-04
DE69834921D1 (de) 2006-07-27
EP1003551A2 (en) 2000-05-31

Similar Documents

Publication Publication Date Title
IS5329A (is) Flutningskerfi fyrir antígen þar sem monoglýseríðeða díglýseríð afleiður eru ónæmisglæðar
WO2001081609A3 (en) Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
GB9808327D0 (en) Antidiotypic compounds
BG101995A (en) Saponin and sterol-containing vaccines
WO1999066879A3 (en) Systemic immune activation method using nucleic acid-lipid complexes
AU1593001A (en) Recombinant gelatin in vaccines
NZ532665A (en) Neisseria meningitidis antigens and compositions
ATE229978T1 (de) Helicobacter proteine und impstoffe
DZ2462A1 (fr) Vaccin antigrippal.
IL154913A0 (en) Composition comprising immunogenic microparticles
NO982497D0 (no) Vaksine-sammensetninger for inntak gjennom nesen
PL1635863T3 (pl) Kompozycje do wywoływania, wzmacniania i utrzymywania odpowiedzi immunologicznych na epitopy ograniczone do MHC klasy I do celów profilaktycznych i leczniczych
CY1108074T1 (el) Ανοσολογικες μεθοδοι για τη ρυθμιση της μυοστατινης σε σπονδυλωτα
WO2001021207A3 (en) Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
EP1594536A4 (en) ADJUVANT INFLUENZA VACCINE
EP2275122A3 (en) Protein-based streptococcus pneumoniae vaccines
DE69726712D1 (de) Iscom oder iscom-matrix, welche einen gegen die schleimhaut gerichteten wirkstoff und ein antigen enthält
ES2177927T3 (es) Composicion para provocar una reaccion inmunologica a un determinante antigenico no proteinico.
DK1259259T3 (da) Mucosal adjuvansformulering
DK0892054T3 (da) Clostridium perfringens-vaccine
CY1107322T1 (el) Συνδυασμενο εμβολιο κατα της hπατιτιδας α και ηπατιτιδας β
HRP20080612T3 (hr) Kombinacija tenofovira, ritonavira i tmc114
FR2715304B1 (fr) Vaccin anti-allergique.
WO1999016466A3 (en) Vaccine compositions and methods of enhancing vaccine efficacy